Pretrial Clashes Intensify In Neurontin Off-Label MDL

Law360, New York (February 11, 2010, 6:55 PM EST) -- With a trial in multidistrict litigation over Pfizer Inc.'s alleged off-label marketing of Neurontin barely more than a week away, the drugmaker is seeking depositions related to a Web site owned by plaintiff Kaiser Foundation Health Plan Inc. that Pfizer argues actually touts the drug’s off-label uses.

In at least two separate deposition battles ahead of a Feb. 22 trial, Pfizer contends that Kaiser's health care Web site recommends a generic version of Neurontin for the very conditions Kaiser argues the epilepsy drug is ineffective at...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.